机构:[a]Department of Respiratory Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China诊疗科室呼吸内科首都医科大学附属天坛医院[b]Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China[c]Department of Pulmonary and Critical Care Medicine, Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China[d]National Clinical Research Center for Respiratory Diseases, Beijing 100029, China[e]Department of Respiratory Medicine, Capital Medical University, Beijing 100069, China[f]Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China[g]Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China
Interleukin (IL)-1 beta and IL-18 play central and detrimental roles in the development of acute lung injury (ALI), and mammalian target of rapamycin (mTOR) is involved in regulating IL-1 beta and IL-18 production. However, it is not clear whether the mTOR specific inhibitor rapamycin can attenuate lipopolysaccharide (LPS)-induced ALI by modulating IL-1 beta and IL-18 production. In this study, we found that rapamycin ameliorated LPS-induced ALI by inhibiting NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated IL-1 beta and IL-18 secretion. Mechanistically, elevated autophagy and decreased nuclear factor (NF)-kappa B activation were associated with downregulated IL-1 beta and IL-18. Moreover, rapamycin reduced leukocyte infiltration in the lung tissue and bronchoalveolar lavage fluid (BALF), and contributed to the alleviation of LPS-induced ALI. Consistently, rapamycin also significantly inhibited IL-1 beta and IL-18 production by RAW264.7 cells via increased autophagy and decreased NF-kappa B signaling in vitro. Our results demonstrated that rapamycin protects mice against LPS-induced ALI partly by inhibiting the production and secretion of IL-1 beta and IL-18. mTOR and rapamycin might represent an appropriate therapeutic target and strategy for preventing ALI induced by LPS.
基金:
National Natural Science Foundation of China, ChinaNational Natural Science Foundation of China [81373114]; National Science Grant for Distinguished Young Scholars [81425001/H0104]; National Key Technology Support Program from Ministry of Science and Technology, China [2015BA112B11]; Beijing Science and Technology Project [D151100002115004]; Beijing Municipal Natural Science Foundation, ChinaBeijing Natural Science Foundation [7182013]
第一作者机构:[a]Department of Respiratory Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China[b]Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China
通讯作者:
通讯机构:[b]Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China[c]Department of Pulmonary and Critical Care Medicine, Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China[d]National Clinical Research Center for Respiratory Diseases, Beijing 100029, China[e]Department of Respiratory Medicine, Capital Medical University, Beijing 100069, China[f]Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China[g]Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China[*1]Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China
推荐引用方式(GB/T 7714):
Xuehong Jia,Bin Cao,Yunqing An,et al.Rapamycin ameliorates lipopolysaccharide-induced acute lung injury by inhibiting IL-1 beta and IL-18 production[J].INTERNATIONAL IMMUNOPHARMACOLOGY.2019,67:211-219.doi:10.1016/j.intimp.2018.12.017.
APA:
Xuehong Jia,Bin Cao,Yunqing An,Xulong Zhang&Chen Wang.(2019).Rapamycin ameliorates lipopolysaccharide-induced acute lung injury by inhibiting IL-1 beta and IL-18 production.INTERNATIONAL IMMUNOPHARMACOLOGY,67,
MLA:
Xuehong Jia,et al."Rapamycin ameliorates lipopolysaccharide-induced acute lung injury by inhibiting IL-1 beta and IL-18 production".INTERNATIONAL IMMUNOPHARMACOLOGY 67.(2019):211-219